Aspire Biopharma Holdings (ASBP) Prepaid Assets (2022 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Prepaid Assets came in at $1.0 million in Q2 2026, up 28.95% year-over-year from $783189.0 in Q2 2025, and up 13.46% quarter-over-quarter from $890149.0 in Q1 2026.
Analysis
Aspire Biopharma Holdings (ASBP) Prepaid Assets (2022 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Prepaid Assets for 5 consecutive years, with $1.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Prepaid Assets rose 28.95% year-over-year to $1.0 million in Q2 2026; TTM through Jun 2026 was $1.0 million, a 28.95% increase from a year earlier, with the FY2025 full-year figure at $55102.0, down 61.83% from the prior year.
- Prepaid Assets was $1.0 million for Q2 2026 at Aspire Biopharma Holdings, up from $890149.0 in the prior quarter.
- Over five years, Prepaid Assets peaked at $1.0 million in Q2 2026 and troughed at $43052.0 in Q2 2024.
- A 5-year average of $462600.4 and a median of $591303.0 in 2023 frame the typical range for Prepaid Assets.
- Across the five-year window, Prepaid Assets sank 89.77% in 2024 and surged 1719.17% in 2025, its largest moves.
- Over 5 years, Prepaid Assets stood at $600493.0 in 2022, then plunged by 86.47% to $81223.0 in 2023, then surged by 77.73% to $144356.0 in 2024, then tumbled by 61.83% to $55102.0 in 2025, then jumped by 1732.89% to $1.0 million in 2026.
- The last three Prepaid Assets figures came in at $1.0 million (Q2 2026), $890149.0 (Q1 2026), and $55102.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Aspire Biopharma Holdings | 64.13 Mn | 51.96 Mn | -30,086.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.01 Mn |
| Mar 31, 2026 | 890,149.00 |
| Dec 31, 2025 | 55,102.00 |
| Sep 30, 2025 | 419,421.00 |
| Jun 30, 2025 | 783,189.00 |
| Mar 31, 2025 | 618,971.00 |
| Dec 31, 2024 | 144,356.00 |
| Jun 30, 2024 | 43,052.00 |
| Mar 31, 2024 | 65,577.00 |
| Dec 31, 2023 | 81,223.00 |
| Sep 30, 2023 | 253,082.00 |
| Jun 30, 2023 | 420,943.00 |
| Mar 31, 2023 | 591,303.00 |
| Dec 31, 2022 | 600,493.00 |
| Sep 30, 2022 | 613,357.00 |
| Jun 30, 2022 | 629,129.00 |
| Mar 31, 2022 | 644,901.00 |